Organism: Homo sapiens
Gene: 39509_at
Selected probe(set): 228993_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39509_at (228993_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):3.4029312
Number of Samples:3 / 3

Experimental	influenza virus study 10 (A/H5N2)
	Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection.
Control	influenza virus study 4 (A/H1N1)
	Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

Relative Expression (log2-ratio):3.2973318
Number of Samples:3 / 3

Experimental	influenza virus study 9 (A/H5N2)
	Human carcinoma cell line A549 infected with influenza A virus subtype A/duck/Malaysia/F118/08/2004(H5N2). Samples were taken 10 hours post-infection.
Control	influenza virus study 4 (A/H1N1)
	Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

Relative Expression (log2-ratio):3.2367764
Number of Samples:3 / 3

Experimental	influenza virus study 11 (A/H5N3)
	Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control	influenza virus study 4 (A/H1N1)
	Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

Relative Expression (log2-ratio):3.1402168
Number of Samples:3 / 3

Experimental	influenza virus study 9 (A/H9N2)
	Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection.
Control	influenza virus study 4 (A/H1N1)
	Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

Relative Expression (log2-ratio):3.1361485
Number of Samples:2 / 2

Experimental	ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control	ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).

Relative Expression (log2-ratio):-2.8996105
Number of Samples:5 / 5

Experimental	colorectal cancer study 33 (carcinoma; colonic mucosa)
	Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control	normal colon mucosa sample
	Histopathological normal colon mucosa sample obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer.

Relative Expression (log2-ratio):2.7568398
Number of Samples:3 / 7

Experimental	TCDD study 1 (24h)
	HepG2 cells exposed to 10nM 2,3,7,8-tetrachloro dibenzo-p-dioxin (TCDD) in DMSO solvent for 24 hours. ATC code:---
Control	vehicle (DMSO) treated HepG2 cell sample
	HepG2 cells exposed to DMSO solvent for 24 hours.

Relative Expression (log2-ratio):-2.746089
Number of Samples:3 / 3

Experimental	hypoxia study 2
	Monocyte derived dendritic cells were incubated in six-well culture plates for 4 days under hypoxic conditions.
Control	untreated monocyte-derived dendritic cell sample
	Monocyte derived dendritic cells were incubated in six-well culture plates for 4 days under normoxic conditions.

Relative Expression (log2-ratio):2.6794338
Number of Samples:3 / 4

Experimental	stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast)
	Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control	stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
	Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

Relative Expression (log2-ratio):2.6750755
Number of Samples:2 / 2

Experimental	ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control	ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).